Related references
Note: Only part of the references are listed.Validation of soluble amyloid- precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases
Linda J. C. van Waalwijk van Doorn et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Amyloid-β Protein Precursor Cleavage Products in Postmortem Ventricular Cerebrospinal Fluid of Alzheimer's Disease Patients
Daniela Hartl et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System
Justyna A. Dobrowolska et al.
PLOS ONE (2014)
Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
Marta Pera et al.
ACTA NEUROPATHOLOGICA (2013)
Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid
Panagiotis Alexopoulos et al.
ALZHEIMERS & DEMENTIA (2012)
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
Hugo Vanderstichele et al.
ALZHEIMERS & DEMENTIA (2012)
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease
Lucia Chavez-Gutierrez et al.
EMBO JOURNAL (2012)
Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer's Disease
Christoffer Rosen et al.
NEUROMOLECULAR MEDICINE (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease
R. Perneczky et al.
NEUROLOGY (2011)
Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid
Audrey Gabelle et al.
BRAIN RESEARCH (2010)
Amyloid beta and APP as biomarkers for Alzheimer's disease
Henrik Zetterberg et al.
EXPERIMENTAL GERONTOLOGY (2010)
Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
Erik Portelius et al.
MOLECULAR NEURODEGENERATION (2010)
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study
P. Lewczuk et al.
MOLECULAR PSYCHIATRY (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
Henrik Zetterberg et al.
ARCHIVES OF NEUROLOGY (2008)
What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: A review
JM Ringman
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2005)
Amyloid β 38, 40, and 42 species in cerebrospinal fluid:: more of the same?
NS Schoonenboom et al.
ANNALS OF NEUROLOGY (2005)
Mild cognitive impairment -: beyond controversies, towards a consensus:: report of the International Working Group on Mild Cognitive Impairment
B Winblad et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients
A Olsson et al.
EXPERIMENTAL NEUROLOGY (2003)
The amyloid-beta (A beta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated A beta peptide
P Lewczuk et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2003)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
C Nilsberth et al.
NATURE NEUROSCIENCE (2001)
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease
PD Mehta et al.
ARCHIVES OF NEUROLOGY (2000)
Share Paper
